2016-17 Report on Plans and Priorities (RPP) - Supplementary Information Tables

Horizontal Initiatives

Name of horizontal initiative

National Anti-Drug Strategy

Lead department(s)

Department of Justice Canada

Federal partner organization(s)

  • Health Canada;
  • Canadian Institutes of Health Research;
  • Public Safety Canada;
  • Royal Canadian Mounted Police;
  • Correctional Service Canada;
  • Parole Board of Canada;
  • Public Prosecution Service of Canada;
  • Canada Border Services Agency;
  • Global Affairs Canada;
  • Canada Revenue Agency;
  • Public Services and Procurement Canada; and
  • Financial Transactions and Reports Analysis Centre of Canada.

Non federal and non governmental partner(s)

not applicable

Start date of the horizontal initiative

2007-08 (First year of the National Anti-Drug Strategy)

First reporting cycle (2007-08 to 2011-12)

Second reporting cycle (2012-13 to 2016-17)

End date of the horizontal initiative

2016-17 and Ongoing

Total federal funding allocated (start to end date) (dollars)

First reporting cycle (2007-08 to 2011-12): $563.4M

Second reporting period (2012-13 to 2016-17): $574.3M

Funding contributed by non federal and non governmental partners

not applicable

Description of the horizontal initiative

The National Anti-Drug Strategy was launched by the Government of Canada in 2007, with a focus on illicit drugs and a particular emphasis on youth. Through Speech from the Throne 2013 and Economic Action Plan 2014, the Government of Canada expanded the Strategy to include prescription drug abuse. The goal of the Strategy is to contribute to safer and healthier communities through coordinated efforts to prevent illicit drug use and prescription drug abuse, treat dependency, and reduce production and distribution of illicit drugs. It encompasses three action plans: prevention, treatment and enforcement.

The Prevention Action Plan supports efforts to prevent youth from using illicit drugs and abusing prescription drugs by enhancing their awareness and understanding of the harmful social and health effects, and to develop and implement community-based interventions and initiatives. The Treatment Action Plan supports effective treatment and rehabilitation systems and services by developing and implementing innovative and collaborative approaches. The Enforcement Action Plan aims to contribute to the disruption of illicit drug operations in a safe manner, particularly targeting criminal organizations.

Shared outcome(s)

  • Reduced prescription drug abuse in Canada;
  • Reduced demand for illicit drugs in targeted populations and areas;
  • Reduced negative health and social impacts and crime related to illicit drug use and prescription drug abuse; and
  • Reduced supply of illicit drugs.

Governance structures

The governance structure of the Strategy consists of an Assistant Deputy Minister Steering Committee (ADMSC) and Director General level working groups on policy and performance, prevention and treatment, enforcement, and communications. The governance structure is supported by the Youth Justice and Strategic Initiatives Section of the Department of Justice Canada.

The ADMSC, which is chaired by the Department of Justice Canada, oversees the implementation of the Strategy, making decisions necessary to advance the initiative, where required, and ensuring appropriate and timely outcomes for the initiative and accountability in the expenditure of initiative resources. The ADMSC prepares questions and makes recommendations for the consideration of Deputy Ministers, where appropriate. It also oversees the work of the four Director general level working groups.

The Prevention and Treatment Working Group, chaired by Health Canada, oversees the implementation of the Prevention and Treatment Action Plans, as well as the work of a Prevention and Treatment Sub-Working Group. The Enforcement Working Group, chaired by Public Safety and Emergency Preparedness Canada, oversees the implementation of the Enforcement Action Plan, as well as the work of a new Sub-Committee on Information Sharing and Surveillance. The Policy and Performance Working Group, chaired by the Department of Justice Canada, oversees policy directions and outcomes for the Strategy, as well as the work of the Sub-Committee on Evaluation and Reporting. The Communications Working Group, chaired by the Department of Justice Canada, oversees communication of the Strategy, which includes making the decisions necessary to advance communication of the initiative to the public and stakeholder groups and ensuring coordination of such communications. It also oversees the work of a Communications Sub-Working Group.

Planning highlights

In 2016-17, the 12 federal partner departments and agencies involved in the National Anti-Drug Strategy will continue their work to contribute to safer and healthier communities through coordinated efforts to prevent illicit drug use and prescription drug abuse, treat dependency, and reduce production and distribution of illicit drugs. In the final year of its current five-year reporting cycle, key planning highlights will include:

  • contributing to international drug policy discussions, including the United Nations General Assembly Special Session on the World Drug Problem (UNGASS) in April 2016;
  • collaborating on relevant domestic drug policy development, including advancement of Government drug policy priorities; and
  • undertaking a horizontal evaluation of the Strategy, to be completed in 2017.

Results to be achieved by non federal and non governmental partners

not applicable

Contact information

Danièle Ménard
Director General and General Counsel
Youth Justice and Strategic Initiatives Section
Justice Canada
613-954-2370
Danièle.Ménard@justice.gc.ca

Planning Information
Link to department's Program Alignment Architecture Contributing programs and activities Total allocation (from start to end date) (dollars) 2016–17 Planned spending (dollars) 2016–17 Expected results
Department of Justice
Stewardship of the Canadian Legal Framework Drug Treatment Court Funding Program $18.2M $3.6M [ER 1.1]
Youth Justice Fund $7.9M $1.6M [ER 1.2]
Justice Canada Lead Role for the National Anti-Drug Strategy $1.2M $0.2M [ER 1.3]
Internal Services Justice Canada Lead Role for the National Anti-Drug Strategy $1.1M $0.2M
National Anti-Drug Strategy $0.2M $0.0M [ER 1.4]
Health Canada
Controlled Substances Anti-Drug Strategy Initiatives (ADSI) $28.8M $0.0M [ER 2.1]
Anti-Drug Strategy Initiatives (ADSI) $54.0M $0.0M
Anti-Drug Strategy Initiatives (ADSI) – consolidation of DSCIF and DTFP $45.6M $22.8M
First Nations and Inuit Mental Health and Addictions National Native Alcohol and Drug Abuse Program (NNADAP) $58.4M $12.1M [ER 2.2]
Controlled Substances Office of Controlled Substances $31.2M $6.2M [ER 2.3]
Transfer to Regional and Programs Branch for Compliance and Enforcement Activities $9.8M $2.0M
Controlled Substances / First Nations and Inuit Mental Health and Addictions Drug Analysis Services $54.5M $10.8M [ER 2.4]
Prescription Drug Abuse $21.4M $9.7M [ER 2.5]
Canadian Institutes of Health Research
Horizontal Health Research Initiatives Research on Drug Treatment Models $7.875M $1.975M [ER 3.1]
Public Safety Canada
Law Enforcement National Coordination of Efforts to Improve Intelligence, Knowledge, Management, Research, Evaluation $3.3M $0.6M [ER 4.1]
Internal Services $0.1M $0.0M [ER 4.2]
Royal Canadian Mounted Police
Federal Policing (formerly Drugs and Organized Crime) Federal Policing Public Engagement (FPPE) $12.5M $2.2M [ER 5.1]
Federal Policing Project-Based Investigations $94.6M $16.7M [ER 5.2]
Internal Services $12.6M $2.9M  
Correctional Service Canada
Correctional Interventions Case Preparation and Supervision of Provincial Offenders $5.9M $0.6M [ER 6.1]
Community Supervision Case Preparation and Supervision of Provincial Offenders $2.2M $1.3M
Parole Board of Canada
Conditional Release Decisions Conditional Release Decisions $5.6M $1.1M [ER 7.1]
Conditional Release Decisions Openness and Accountability Conditional Release Decisions Openness and Accountability $2.1M $0.4M [ER 7.2]
Internal Services $1.7M $0.4M [ER 7.3]
Public Prosecution Service of Canada
Drug, Criminal Code, and terrorism prosecution program Prosecution and Prosecution-related Services $17.0M $3.4M [ER 8.1]
Prosecution of Serious Drug Offences under the CDSA $36.2M $7.2M [ER 8.2]
Internal Services Prosecution and Prosecution-related Services $2.5M $0.5M [ER 8.3]
Prosecution of Serious Drug Offences under the CDSA $5.3M $1.1M
Canada Border Services Agency
Risk Assessment Targeting Intelligence Security Screening $9.8M $2.1M [ER 9.1]
Criminal Investigations $1.4M $0.2M [ER 9.2]
Internal Services $8.8M $1.3M [ER 9.3]
Global Affairs Canada
Diplomacy, Advocacy and International Agreements Annual Voluntary Contributions to the United Nations Office on Drugs and Crime (UNODC) and the Inter-American Drug Abuse Control Commission (CICAD) of the Organization of American States (OAS) $4.5M $0.9M [ER 10.1]
Canada Revenue Agency
Reporting Compliance Small and Medium Enterprises Directorate $5.0M $1.0M [ER 11.1]
Public Services and Procurement Canada
Specialized Programs and Services Forensic Accounting Management Group $3.0M $0.6M [ER 12.1]
Financial Transactions and Reports Analysis Centre of Canada
Financial Intelligence Program Financial Intelligence Program $0.0M $0.0M [ER 13.1]
Total for all federal organizations $574.3M $115.7M  

Expected Results

Department of Justice

ER 1.1

Reduced drug substances relapse among drug treatment court participants.

ER 1.2

To work collaboratively with interested provinces and territories as well as other stakeholders in order to identify gaps in drug treatment programs for youth in the justice system.

To introduce, pilot and evaluate a number of drug treatment options in communities for youth involved in the youth justice system.

To share knowledge of the piloted drug treatment programs and promising practices with provinces and territories as well as other interested stakeholders.

ER 1.3

Effective leadership of the federal response to concerns around illicit drug prevention, treatment, and enforcement, and prescription drug abuse through:

  • Exercising overarching responsibility for policy and coordination;
  • Maintaining the Strategy's governance structure;
  • Leading and coordinating all National Anti-Drug Strategy communications activities; and
  • Taking lead responsibility for accountability, evaluation and performance reporting.

ER 1.4

Support the work of Justice programs by providing key corporate services.

Health Canada

ER 2.1

In December 2014, the Anti-Drug Strategy Initiatives (ADSI) was created, which consolidated two previous Health Canada contribution funding programs, the Drug Strategy Community Initiatives Fund (DSCIF) and the Drug Treatment Funding Program (DTFP), into one joint fund. ADSI will continue to deliver the National Anti-Drug Strategy Prevention and Treatment Action Plan mandates. Reporting on ADSI has commenced in 2015-16, as specified in the 2015-16 RPP. DSCIF and DTFP figures reflect Grants & Contributions funding only.

Through the Anti-Drug Strategy Initiatives Program, Health Canada will continue to deliver the National Anti-Drug Strategy Prevention and Treatment Action Plan mandates for illicit and prescription drug abuse. A call for proposals for substance abuse initiatives will be launched in 2016-17.

ER 2.2

Health Canada, through the First Nations Inuit Health Branch (FNIHB), plans to increase the availability of, and access to, effective treatment services and programs for First Nations and Inuit populations in areas of need. The progress of this plan will be measured by the nature of new or enhanced services that have been made available through funding in targeted areas and are based on research or best practices. FNIHB also plans to improve treatment systems, programs and services to address drug dependency in First Nations and Inuit populations in areas of need.

Total Allocation and Planned Spending increased from figures reported in the 2015-16 Reports on Plans and Priorities for National Native Alcohol and Drug Abuse Program (NNADAP) to reflect renewed funding received for Mental Wellness Teams under NADS. Mental Wellness Teams are recognized as a key initiative resulting from planning and policy development partnerships with National Aboriginal Organizations.

ER 2.3

Health Canada, through the Office of Controlled Substances (OCS), will renew and enhance the robustness and transparency of its processes to authorize and issue licenses, permits, registrations, and authorizations to perform legitimate activities with controlled substances, precursor chemicals, and industrial hemp. Health Canada will also continue working with partners and regulated parties to reduce the risk of diversion of controlled substances, precursor chemicals by promoting and monitoring compliance with the Controlled Drugs and Substances Act and its regulations.

ER 2.4

Health Canada, through the Drug Analysis Services (DAS), plans to increase effectiveness in gathering, analyzing, and sharing intelligence and analyzing evidence related to clandestine laboratories and drug analyses. DAS will also increase awareness of illicit drug and precursor chemical issues for enforcement officials through targeted training, increase safety in dismantling illicit drug operations, reduce risks associated with illicit drug production, and improve intelligence and evidence gathering.

ER 2.5

The Prescription Drug Abuse (PDA) TB Submission provided five year funding (2014-15 to 2018-19) for the Health Portfolio of $443.M. PDA's approved allocation for the five-year period being reported (2012-13 to 2016-17) is $21.4M.

Health Canada will continue to engage provinces and territories to advance collaborative efforts to combat prescription drug abuse (PDA). Health Canada will serve as the secretariat for the F/P/T Prescription Monitoring Program Network, which will facilitate the creation of new prescription monitoring programs (PMPs) and enhance existing PMPs through sharing best practices, data, advice, and mentoring. The department will also fund and oversee the Canadian Institute for Health Information's efforts to develop a national approach to prescription drug surveillance.

Health Canada, through the Office of Drug Science and Surveillance (ODSS) will improve research and data analysis to support work on PDA, and will expand internal monitoring and reporting on PDA. ODSS will continue working on the costs of the PDA project, developing methodology and adding new data sources as they become available.

In an effort to contribute to the prevention of PDA, the marketing campaign, led by the Communications and Public Affairs Branch (CPAB), Health Canada will continue to increase awareness about the harms and risks associated with PDA among parents and youth, and educate Canadians on the importance of safely storing, monitoring, and disposing of prescription drugs.

Health Canada, through the First Nations and Inuit Health Branch (FNIHB), will continue to enhance prevention and treatment capacity for PDA in First Nations communities across Canada. Priority areas will include: PDA-specific crisis intervention teams in Manitoba and Saskatchewan First Nation communities; increased case management supports in select treatment centres and First Nations communities; and, increased access to PDA prevention training.

Health Canada, through the Office of Controlled Substances and the Regions and Programs Bureau, is undertaking inspections of pharmacies across Canada to ensure the security of pharmaceuticals contained in these facilities and minimize the potential diversion of these drugs for illicit use. Health Canada is also updating and disseminating drug destruction guidelines for law enforcement and pharmacies to ensure appropriate collection, handling, and disposal of unused or expired pharmaceuticals.

Canadian Institutes of Health Research

ER 3.1

In 2015-16, CIHR established the Canadian Research Initiative in Substance Misuse (CRISM), a national consortium in substance misuse by funding four research Nodes (in each of British Columbia, Prairies, Ontario, and Quebec/Maritimes) that enhances collaboration between researchers and service providers.

In 2016-17, CIHR will continue to fund CRISM to undertake national studies of substance misuse research in Canada. Recipients of the Prescription Drug Abuse Knowledge Synthesis grants will implement their research, supporting partnerships between researchers and knowledge users to produce scoping reviews and syntheses that respond to the information needs of knowledge users in the area of prescription drug abuse.

In 2016-17, CIHR will also implement a governance and reporting strategy to provide appropriate oversight of CRISM based on CIHR's Governance Strategy for CIHR-funded Major Initiatives. As part of this governance, two meetings will be held for the Executive Committee of the CRISM to provide a national coordination of the CRISM's activities, including research priority setting, establishing common measure elements for trials, overseeing aspects of research ethics, defining a knowledge transition plan, and assessing progress.

Additional information:

The Canadian Institutes of Health Research (CIHR)'s total allocation from 2012-13 to 2016-17 reflects the additional temporary funding received to address prescription drug abuse as per the 2014 Economic Action Plan.

Public Safety Canada

ER 4.1

Safer communities and more effective policing through strategic national law enforcement policies.

ER 4.2

Support the work of the program by providing key corporate services.

Royal Canadian Mounted Police

ER 5.1

In 2016-17 the RCMP, through partnerships with internal and external departments, will increase awareness of organized crime and the nature, extent and consequences of substance use and abuse among youth, professionals, and the general public.

ER 5.2

In 2016-17 the RCMP will continue efforts, through initiatives that will assist in the disruption of organized criminal networks behind illegal drug enterprises.

Correctional Service Canada

ER 6.1

Timely case preparation and supervision of provincial offenders with a drug offence (Schedule II). In 2016-17, CSC expects to supervise approximately 45 provincial offenders convicted of a drug offence (Schedule II), approximately 30 of those with a residency requirement. It is expected that a total number of 840 case preparation reports (pre- and post-release) will be completed.

Parole Board of Canada

ER 7.1

This funding will provide the PBC the capacity for effective management of its legislated responsibilities for parole decision-making for offenders in relation to the requirements of the Safe Streets and Communities Act. PBC will collect information and report on workloads and outcomes of parole for provincial offenders incarcerated as a result of Mandatory Minimum Penalties (e.g., the number and proportion of offenders who successfully complete their parole).

ER 7.2

This funding will provide PBC with the capacity to provide information and assistance to victims of crime, observers at hearings and individuals who seek access to decision registry in relation to the requirements of the Safe Streets and Communities Act (Mandatory Minimum Penalties). In a similar manner, PBC will report on the extent of involvement of victims and observers in conditional release processes and the level of satisfaction of these individuals with the information and assistance provided by PBC. Effective management of both these responsibilities will contribute to public safety and reinforce public confidence in the justice system.

ER 7.3

Support the work of the program by providing key corporate services.

Public Prosecution Service of Canada

ER 8.1

Provision of pre-charge legal advice and litigation support, as well as prosecution of serious drug offences under the Controlled Drugs and Substances Act (CDSA) in response to the workload generated by the enhanced RCMP dedicated anti-drug teams and criminal intelligence and technical operations support staff.

ER 8.2

Provision of prosecution-related advice and litigation support during police investigations, and prosecution of drug charges under the CDSA resulting from mandatory minimum penalties.

ER 8.3

Support the work of the program by providing key corporate services.

Canada Border Services Agency

ER 9.1

Continue to increase awareness and capacity to gather information and intelligence of illicit drug issues relative to the border.

Continue to increase intelligence support to regional enforcement activities to interdict goods entering and leaving Canada under the Strategy.

Continue to improve relationships and communication with partner agencies under the Strategy to identify opportunities and improve intelligence activities such as targeting and information sharing related to illicit drugs and other goods (such as precursor chemicals) identified under the Strategy as they relate to the border.

ER 9.2

Continue to conduct additional sampling, analysis and increased use of mobile laboratory capabilities to assist in the detection of precursor chemicals at the ports of entry.

Continue to work collaboratively with other Law Enforcement Agencies (LEA) when goods that fall within the Controlled Drugs and Substances Act (CDSA) schedules are intercepted and a border nexus identified. Activities include gathering evidence at ports of entry to participation in controlled deliveries and joint investigations with partner LEA.

ER 9.3

Support the work of the CBSA programs by providing key corporate services.

Continuation of additional sampling analysis and increased use of mobile laboratory capabilities to assist in the detection of precursor chemicals at the ports of entry.

Global Affairs Canada

ER 10.1

To assist UNODC in fulfilling its mandate in the fight against drugs and transnational crime ($0.8M).

To assist CICAD to fulfill its mandate in the fight against drugs and crime in the Americas ($0.1M).

Canada Revenue Agency

ER 11.1

30 audits of taxpayers involved in the production and distribution of illegal drugs resulting in (re)assessment of $2.0M of federal taxes.

Leads will be obtained by the Criminal Investigations Directorate, from the RCMP, and from other enforcement agencies involved in enforcement activities relating to illegal drug use, production, and distribution and forwarded to the Small and Medium Enterprises Directorate to be considered for audit.

Emphasis will continue to be placed on intelligence-led strategic file selection in an effort to reduce the profitability of illegal/criminal activities in this sector.

Public Services and Procurement Canada

ER 12.1

Increased operational capacity to provide forensic accounting services to law enforcement agencies. Forensic accounting services assist law enforcement and prosecution agencies in determining whether the assets of suspects were derived from criminal activities, thereby allowing the Government of Canada to seize the assets and remove the financial incentives for engaging in criminal activities.

Financial Transactions and Reports Analysis Centre of Canada

ER 13.1

In 2016-17, FINTRAC will continue to be an unfunded partner within the National Anti-Drug Strategy. Given the importance of the Strategy, FINTRAC will continue to work with law enforcement and intelligence agencies to ensure they receive financial intelligence related to drug production and distribution that is useful for further actions.

Date modified: